v3.25.1
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Net revenues $ 13,343 $ 12,310
Cost of products sold 4,002 4,094
Selling, general and administrative 3,293 3,315
Research and development 2,067 1,939
Acquired IPR&D and milestones 248 164
Total operating costs and expenses 9,610 9,512
Operating earnings 3,733 2,798
Interest expense, net 627 453
Net foreign exchange loss 4 4
Other expense, net 1,441 586
Earnings before income tax expense 1,661 1,755
Income tax expense 372 383
Net earnings 1,289 1,372
Net earnings attributable to noncontrolling interest 3 3
Net earnings attributable to AbbVie Inc. $ 1,286 $ 1,369
Per share data    
Basic earnings per share (in dollars per share) $ 0.72 $ 0.77
Diluted earnings per share (in dollars per share) $ 0.72 $ 0.77
Weighted-average basic shares outstanding (in shares) 1,768 1,769
Weighted-average diluted shares outstanding (in shares) 1,772 1,773